Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.
about
Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitorThe infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.Targeting of adenosine receptors in ischemia-reperfusion injury.Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?Potential therapeutic benefits of strategies directed to mitochondria.Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.Acute adenosinergic cardioprotection in ischemic-reperfused hearts.Polyphenol (-)-epigallocatechin gallate-induced cardioprotection may attenuate ischemia-reperfusion injury through adenosine receptor activation: a preliminary studyAll preconditioning-related G protein-coupled receptors can be demonstrated in the rabbit cardiomyocyte.Ecto-5' nucleotidase (CD73)-mediated adenosine generation and signaling in murine cardiac allograft vasculopathyPharmacologic therapeutics for cardiac reperfusion injury.Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusionThe role of nitric oxide in A3 adenosine receptor-mediated cardioprotection.Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptorsAdenosine receptors and reperfusion injury of the heartThere is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Pharmacologic therapy for reducing myocardial infarct size in clinical trials: failed and promising approaches.Adenosine A3 Receptor: A promising therapeutic target in cardiovascular disease.Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in ratA3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogsEffect of repeated ischaemic preconditioning on TLR4 and proinflammatory cytokines TNF-α and IL-1β in myocardial ischaemia-reperfusion injury in a rat model.Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart.Effect of nitric oxide on capillary hemodynamics and cell injury in the pancreas during Pseudomonas pneumonia-induced sepsis.Extracellular inosine is modulated by H2O2 and protects sertoli cells against lipoperoxidation and cellular injury.Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation.Long-term infusion of Met5-enkephalin fails to protect murine hearts against ischemia-reperfusion injury.Contractile effects of adenosine A1 and A2A receptors in isolated murine hearts.Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury.The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium.Caspase inhibition via A3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction.The Polymorphism in ADORA3 Decreases Transcriptional Activity and Influences the Chronic Heart Failure Risk in the Chinese.SIRT1 modulates MAPK pathways in ischemic–reperfused cardiomyocytes
P2860
Q28534483-30029B53-0EBE-446F-85A3-0B73EA7F8D09Q30300583-DF9C4931-9CCE-4C5C-8C3B-CE8D58A497B0Q30429069-C3BAE1F1-EE61-413D-9A42-E615718BF9F8Q31039936-B60EC71A-2FBF-4D4C-9D3D-3511CD579E16Q34025792-C02B817E-E5B6-4B77-A954-894C9F986F92Q34117168-06CD21FF-0C69-4490-9E92-CCF835893F99Q34222754-036D997D-A8E0-49DA-8D92-24E12CA83A37Q35560907-F9018660-137E-41A9-BD55-5A1BEFF8646EQ36354688-A2F770D8-3A36-4FA3-A958-8D997D170F51Q36497689-40A26032-1EE1-4FCE-8DC2-C83593F9214BQ36818237-EF7004EF-DE27-452F-8BD6-6CDFD7CC64AFQ36944008-46C9BDCE-781B-49DA-9AE8-53E6B52C35B7Q37003068-2AF620FC-B967-4923-9541-75044CEA3D50Q37312196-5663A554-9483-4B04-9AF9-D29A90BF0BA7Q37536268-D41A3730-A105-4F16-B156-140614EE0A8BQ37542790-67F80AB3-810B-4095-B1F8-4E3C69D7B7EDQ37565166-4CCA9A00-D923-44E9-82AF-605BD5FAA2DBQ37774394-2E1E27CE-73E2-4439-B41D-8B54ED5B30D1Q37957791-A6578266-2DF0-4113-B84A-1A5C2B6A082EQ38225491-4496AF14-16F4-403E-9E21-35F00AD5F7F9Q38691918-0B012E34-7C01-4821-8743-AD91F75F462AQ40970537-A38A467D-2329-4187-B92B-A839CA14F505Q41772465-D00C445F-6724-43A7-9F1F-066EA302D9E0Q42011387-C4C8E7E8-C46A-418D-9A6E-13DB2A6814B2Q44560614-A1174885-7D68-44B1-B81D-12058CC9FB9FQ44582181-BB2FC0D0-BD2F-4927-B76C-E0CDBF3DC8CCQ44828106-A0501252-838B-4F35-A4F2-933ED3C63182Q45042358-0D11DF4A-4A96-417B-8A8E-1948D8CF70A1Q45154735-884FF95C-14EF-4BC8-B745-861AF98746F9Q46688366-EBB4EBA6-8B8F-49E9-BE35-32DBAB29C1D7Q46962262-8DE8BB85-FB03-41D5-BD71-7CB9375C719CQ48419291-FCA77CE3-EF4D-4021-BAD0-434D310B14F0Q54397580-008CD43D-C31E-426F-9A6B-DE3F1CA1BFB4Q55383408-56A17E0D-C373-4ED9-A8FB-D373745353C3Q58290942-7BC8DFB8-F733-4B77-A15F-A74AD249F8F3
P2860
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Adenosine A(3) receptor activa ...... erfusion/reoxygenation injury.
@en
type
label
Adenosine A(3) receptor activa ...... erfusion/reoxygenation injury.
@en
prefLabel
Adenosine A(3) receptor activa ...... erfusion/reoxygenation injury.
@en
P2860
P1476
Adenosine A(3) receptor activa ...... erfusion/reoxygenation injury.
@en
P2093
Derek M Yellon
Helen L Maddock
P2860
P304
P356
10.1152/AJPHEART.00851.2001
P577
2002-10-01T00:00:00Z